Successful major and minor surgery using factor viii inhibitor bypassing activity in patients with haemophilia A and inhibitors

Haemophilia

Volumn 15, Issue 6, 2009, Pages 1300-1307

  Lauroua, P ^a   Ferrer, A M ^a   Guerin V ^a  

^a HÔPITAL PELLEGRIN   (France)

Author keywords

Blood coagulation factor inhibitors; FEIBA; Haemophilia A; Postoperative haemorrhage; Surgical haemostasis

Indexed keywords

ACTIVATED PROTHROMBIN COMPLEX; BLOOD CLOTTING INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; ERYTHROCYTE TRANSFUSION; HEMATOMA; HEMOPHILIA A; HEMOSTASIS; HIP ARTHROPLASTY; HUMAN; MAJOR SURGERY; MINOR SURGERY; OUTCOME ASSESSMENT; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL;

ADULT; BLOOD COAGULATION FACTOR INHIBITORS; BLOOD COAGULATION FACTORS; FACTOR VIII; HEMOPHILIA A; HEMOSTASIS; HUMANS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 70449580496     PISSN: 13518216     EISSN: 13652516     Source Type: Journal    
DOI: 10.1111/j.1365-2516.2008.01873.x     Document Type: Article

References (23)

1. Négrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Thromb Haemost 1997, 77:1113-9.
2. Quintana-Molina M, Martínez-Bahamonde F, González-García E. Surgery in haemophilic patients with inhibitor: 20 years of experience. Haemophilia 2004, 10(Suppl. 2):30-40.
3. Tjønnfjord GE, Brinch L, Gedde-Dahl T, Brosstad FR. Activated prothrombin complex concentrate (FEIBA®) treatment during surgery in patients with inhibitors to FVIII/IX. Haemophilia 2004, 10:174-8.
4. Tjønnfjord GE. Surgery in patients with hemophilia and inhibitors: a review of the Norwegian experience with FEIBA. Semin Hematol 2006, 43:S18-S21.
5. Kraut EH, Aledort LM, Arkin S, Stine KC, Wong WY. Surgical interventions in a cohort of patients with haemophilia A and inhibitors: an experiential retrospective chart review. Haemophilia 2007, 13:508-17.
6. Rodriguez-Merchan EC, Quintana M, Jimenez-Yuste V, Hernández-Navarro F. Orthopaedic surgery for inhibitor patients: a series of 27 procedures (25 patients). Haemophilia 2007, 13:613-9.
7. Stine KC, Shrum D, Becton DL. Use of FEIBA for invasive or surgical procedures in patients with severe hemophilia A or B with inhibitors. J Pediatr Hematol Oncol 2007, 29:216-21.
8. Tjønnfjord GE. Activated prothrombin complex concentrate (FEIBA) treatment during surgery in patients with inhibitors to FVIII/IX: the updated Norwegian experience. Haemophilia 2004, 10(Suppl. 2):41-5.
9. Baghaei F, Boberg P, Wollter I, Stigendal L. Case report on successful use of activated prothrombin complex concentrate FEIBA® in orthopedic surgery on two patients with factor VIII inhibitors. J Thromb Haemost 2005, 3(Suppl. 1):P1243.
10. Dargaud Y, Lienhart A, Meunier S. Major surgery in a severe haemophilia A patient with high titre inhibitor: use of the thrombin generation test in the therapeutic decision. Haemophilia 2005, 11:552-8.
11. Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006, 12:352-62.
12. Kraut EH. The use of FEIBA for surgery in patients with haemophilia and inhibitors. Haemophilia 2006, 12(Suppl. 5):20-5.
13. Longoni R, Vanelli R, Montani N, Bocchi L, Gamba G. Efficacy and safety of high doses of FEIBA for major surgery in a patient with haemophilia A and high-titre inhibitor. J Thromb Haemost 2007, 5. Suppl. 1, P-M-143
14. Quintana M, Bello IF, Yuste VJ. Orthopaedic surgery in two haemophilic patients with high-response inhibitors. J Thromb Haemost 2007, 5. Suppl. 1, P-W-145
15. Goudemand J, Tagariello G, Lopaciuk F. Cases of surgery in high-responder haemophilia patients. Haemophilia 2004, 10(Suppl. 2):46-9.
16. Rodriguez-Merchan EC. Surgery in haemophilic patients with inhibitors. Haemophilia 2004, 10(Suppl. 2):1-2.
17. Rodriguez-Merchan EC, Rocino A, Ewenstein B. Consensus perspectives on surgery in haemophilia patients with inhibitors: summary statement. Haemophilia 2004, 10(Suppl. 2):50-2.
18. Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002, 8:83-90.
19. Aledort LM. Comparative thrombotic event incidence after infusion of recombinant factor VIIa versus factor VIII inhibitor bypass activity. J Thromb Haemost 2004, 2:1700-8.
20. Aledort LM. Factor VIII inhibitor bypassing activity (FEIBA) - addressing safety issues. Haemophilia 2008, 14:39-43.
21. Astermark J, Donfield SM, DiMichele DM. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007, 109:546-51.
22. Váradi K, Binder BR, Turecek PL. Applications of thrombin generation assay in characterizing FVIII bypassing agents. J Thromb Haemost 2005, 3(Suppl. 1):P0826.
23. Négrier C, Fleury R, Hoots KW. The use of FEIBA during surgeries in haemophilia patients with inhibitors to factor VIII and IX. J Thromb Haemost 2007, 5. Suppl. 1, P-T-172